Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.40 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PPP5C | P53041 | 1/20 | 0.40 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297393 | 1.00 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL15451887 | 0.91 | SMN1; SMN2 (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL19057999 | 0.91 | SMN1; SMN2 (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL671860 | 0.91 | SMN1; SMN2 (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL23139797 | 0.91 | SMN1; SMN2 (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL17035536 | 0.86 | KDM4E (0.39) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL2334133 | 0.83 | SMN1; SMN2 (0.37) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL14216716 | 0.81 | KDM4E (0.36) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL14197579 | 0.81 | KDM4E (0.36) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL7869972 | 0.81 | KDM4E (0.36) | KDM4EGMNNPPM1BLMNAPPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130540-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, AND ELECTRONIC DEVICE | 东莞新能源科技有限公司 | 2024-06-27 | — | — | WO | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| EP-4180434-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022007966-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川海思科制药有限公司 | 2022-01-13 | — | — | WO | disclosed |
| US-8552183-B2 | Process for the covalent coupling of two molecules by means of a diels-alder reaction with inverse electron requirement | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552183-B2 | Process for the covalent coupling of two molecules by means of a diels-alder reaction with inverse electron requirement | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2007144200-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1867638-A1 | Procedure for the Conection of two Molecules via Diels-Alder Reactions with Inverse Electron Demand | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-5221745-A | Antidepressanat, anxiolytic and hypotensive agent | AMERICAN HOME PRODUCTS CORP. (US) | 1993-06-22 | — | — | US | disclosed |
| US-5212170-A | Psychotropic piperidinylmethyl benzodioxans | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-05-18 | — | — | US | disclosed |
| US-5182292-A | Psychotropic piperidinylmethyl benzodioxans | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-01-26 | — | — | US | disclosed |
| US-5134140-A | Psychotropic benzofuran derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| US-4968792-A | Psychotropic benzisothiazole derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-11-06 | — | — | US | disclosed |
| US-4910302-A | Dehydro-3-(2-(2,3-dihydro-1,4-benzdioxan-2-ylmethyl)amino)-ethyl)-1,5-methano-6,7,9-metheno-2H-pentaleno(1,2-d)-azepine-2,4-3H-dione | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | KDM4E 4592/4885GMNN 4713/4885PPM1B 301/4885 |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | CX3CR1, NR3C2, NR4A2 | KDM4E 4605/4885GMNN 3850/4885PPM1B 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.